Nektar Therapeutics (NKTR) Liabilities and Shareholders Equity (2010 - 2026)

Nektar Therapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $763.3 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 197.87% year-over-year to $763.3 million in Q1 2026; TTM through Mar 2026 was $1.6 billion, a 28.16% increase from a year earlier, with the FY2025 full-year figure at $280.4 million, down 7.72% from the prior year.
• Liabilities and Shareholders Equity climbed to $763.3 million in Q1 2026 per NKTR's latest filing, from $280.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.0 billion in Q1 2022 and bottomed at $207.5 million in Q2 2025.
• The 5-year median for Liabilities and Shareholders Equity is $398.0 million (2023), against an average of $496.1 million.
• Across the five-year window, Liabilities and Shareholders Equity sank 45.15% in 2023 and soared 197.87% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $710.6 million in 2022, then plunged by 43.99% to $398.0 million in 2023, then decreased by 23.66% to $303.8 million in 2024, then decreased by 7.72% to $280.4 million in 2025, then jumped by 172.2% to $763.3 million in 2026.
• Per Business Quant, the three latest NKTR Liabilities and Shareholders Equity figures stand at $763.3 million (Q1 2026), $280.4 million (Q4 2025), and $301.3 million (Q3 2025).